Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,669 | -53,479 | -38,086 | -25,768 | -9,400 |
| Depreciation Amortization | 76 | 230 | 173 | 116 | 68 |
| Accounts payable and accrued liabilities | -1,047 | 2,327 | 2,173 | 3,266 | 830 |
| Other Working Capital | -3,230 | 5,573 | 6,042 | 6,669 | 3,133 |
| Other Operating Activity | 2,348 | 3,546 | 1,095 | -1,463 | -2,172 |
| Operating Cash Flow | $-11,522 | $-41,803 | $-28,604 | $-17,180 | $-7,542 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -26 | -9 | -10 | -12 |
| Investing Cash Flow | $N/A | $-26 | $-9 | $-10 | $-12 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 151 | 151 | 151 | 30 |
| Financing Cash Flow | $N/A | $151 | $151 | $151 | $30 |
| Exchange Rate Effect | 121 | 606 | -480 | -188 | -51 |
| Beginning Cash Position | 89,018 | 130,089 | 130,089 | 130,089 | 130,089 |
| End Cash Position | 77,616 | 89,018 | 101,147 | 112,862 | 122,513 |
| Net Cash Flow | $-11,402 | $-41,071 | $-28,943 | $-17,227 | $-7,576 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,522 | -41,803 | -28,604 | -17,180 | -7,542 |
| Capital Expenditure | N/A | -26 | -9 | -10 | -12 |
| Free Cash Flow | -11,522 | -41,828 | -28,613 | -17,190 | -7,554 |